These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 6686682)

  • 21. Nonrenal clearance of furosemide as a cause of diuretic response variability in the rat.
    Lambert C; Caillé G; du Souich P
    J Pharmacol Exp Ther; 1982 Jul; 222(1):232-6. PubMed ID: 7086701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Theophylline-furosemide inactivation?
    Toback JW; Gilman ME
    Pediatrics; 1983 Jan; 71(1):140-1. PubMed ID: 6848968
    [No Abstract]   [Full Text] [Related]  

  • 23. Absorption and excretion of furosemide-S35 in human subjects.
    Calesnick B; Christensen JA; Richter M
    Proc Soc Exp Biol Med; 1966 Oct; 123(1):17-22. PubMed ID: 5924423
    [No Abstract]   [Full Text] [Related]  

  • 24. Furosemide nephrolithiasis causing ureteral obstruction and urinoma in a preterm neonate.
    Alpert SA; Noe HN
    Urology; 2004 Sep; 64(3):589. PubMed ID: 15351602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transient leukopenia/neutropenia associated with stat doses of frusemide in a preterm infant.
    Yeung MY
    J Paediatr Child Health; 1999 Dec; 35(6):591-2. PubMed ID: 10633309
    [No Abstract]   [Full Text] [Related]  

  • 26. Furosemide disposition in normal and proteinuric rats: urinary drug-protein binding as a determinant of drug excretion.
    Green TP; Mirkin BL
    J Pharmacol Exp Ther; 1981 Jul; 218(1):122-7. PubMed ID: 7241373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Furosemide and acute kidney injury in neonates.
    Moghal NE; Shenoy M
    Arch Dis Child Fetal Neonatal Ed; 2008 Jul; 93(4):F313-6. PubMed ID: 18305070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Furosemide does not prevent indomethacin-induced renal side effects in preterm infants.
    Romagnoli C; Zecca E; Papacci P; De Carolis MP; Giannini R; Gallini F; Tortorolo G
    Clin Pharmacol Ther; 1997 Aug; 62(2):181-6. PubMed ID: 9284854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effects of furosemide on renal functions in prematures (author's transl)].
    Tulassay T; Kiszel J; Machay T; Csömör S
    Monatsschr Kinderheilkd; 1982 Jul; 130(7):541-5. PubMed ID: 7110156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The lung of the premature infant: pathophysiology of disease and newer therapies.
    Robbins C; Green R; Lasker M; Wiseman G; Holzman IR
    Mt Sinai J Med; 1994 Oct; 61(5):416-23. PubMed ID: 7799978
    [No Abstract]   [Full Text] [Related]  

  • 31. Development of an optimal furosemide infusion strategy in infants with modeling and simulation.
    Schoemaker RC; van dDer Vorst MM; van Heel IR; Cohen AF; Burggraaf J;
    Clin Pharmacol Ther; 2002 Oct; 72(4):383-90. PubMed ID: 12386640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Analyses for furosemide and its metabolite in body fluids and urine of rabbit by high performance liquid chromatography].
    Yoshitomi H; Ikeda K; Goto S
    Yakugaku Zasshi; 1982 Dec; 102(12):1171-6. PubMed ID: 7182451
    [No Abstract]   [Full Text] [Related]  

  • 33. The metabolism and toxicity of furosemide in the Wistar rat and CD-1 mouse: a chemical and biochemical definition of the toxicophore.
    Williams DP; Antoine DJ; Butler PJ; Jones R; Randle L; Payne A; Howard M; Gardner I; Blagg J; Park BK
    J Pharmacol Exp Ther; 2007 Sep; 322(3):1208-20. PubMed ID: 17556636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose-dependent evaluation of the effects of nebulized furosemide on pulmonary function in ventilated preterm infants.
    Prabhu VG; Keszler M; Dhanireddy R
    J Perinatol; 1998; 18(5):357-60. PubMed ID: 9766411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Quantitative determination of furosemide and its metabolites in urine by means of Sephadex-column chromatography].
    Hajdú P; Hornke I
    Z Klin Chem Klin Biochem; 1970 Jan; 8(1):49-50. PubMed ID: 5415551
    [No Abstract]   [Full Text] [Related]  

  • 36. [Pharmacokinetics and biotransformation of oxametacine in healthy volunteers (author's transl)].
    Vergin H; Ferber H; Brunner F; Kukovetz WR
    Arzneimittelforschung; 1981; 31(3):513-8. PubMed ID: 7194675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HPLC-NMR with severe column overloading: fast-track metabolite identification in urine and bile samples from rat and dog treated with [14C]-ZD6126.
    Lenz EM; D'Souza RA; Jordan AC; King CD; Smith SM; Phillips PJ; McCormick AD; Roberts DW
    J Pharm Biomed Anal; 2007 Feb; 43(3):1065-77. PubMed ID: 17030109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Bioavailability of furosemide in humans].
    Wichliński L; Maruchin J; Wiezowska B
    Acta Pol Pharm; 1978; 35(3):359-63. PubMed ID: 696370
    [No Abstract]   [Full Text] [Related]  

  • 39. Bioavailability of two frusemide preparations.
    Beermann B; Dalén E; Lindström B
    Br J Clin Pharmacol; 1978 Dec; 6(6):537-8. PubMed ID: 728325
    [No Abstract]   [Full Text] [Related]  

  • 40. Uric acid excretion related to pharmacokinetics of frusemide [proceedings].
    Roberts CJ; Daneshmend T; Hopton M
    Br J Clin Pharmacol; 1979 Oct; 8(4):394P. PubMed ID: 508532
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.